HRP20210718T1 - Ugljikohidratni sastav za dijalizu - Google Patents
Ugljikohidratni sastav za dijalizu Download PDFInfo
- Publication number
- HRP20210718T1 HRP20210718T1 HRP20210718TT HRP20210718T HRP20210718T1 HR P20210718 T1 HRP20210718 T1 HR P20210718T1 HR P20210718T T HRP20210718T T HR P20210718TT HR P20210718 T HRP20210718 T HR P20210718T HR P20210718 T1 HRP20210718 T1 HR P20210718T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition according
- content
- solution
- glucan molecules
- less
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 31
- 150000001720 carbohydrates Chemical class 0.000 title claims 2
- 238000000502 dialysis Methods 0.000 title 1
- 229920001503 Glucan Polymers 0.000 claims 14
- 239000000243 solution Substances 0.000 claims 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 9
- 239000007788 liquid Substances 0.000 claims 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 3
- 102000015636 Oligopeptides Human genes 0.000 claims 3
- 108010038807 Oligopeptides Proteins 0.000 claims 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 3
- 239000000385 dialysis solution Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 239000013589 supplement Substances 0.000 claims 2
- 102000013142 Amylases Human genes 0.000 claims 1
- 108010065511 Amylases Proteins 0.000 claims 1
- 241000792859 Enema Species 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 235000019418 amylase Nutrition 0.000 claims 1
- 229940025131 amylases Drugs 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004140 cleaning Methods 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 238000001784 detoxification Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 239000007920 enema Substances 0.000 claims 1
- 229940095399 enema Drugs 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 238000005194 fractionation Methods 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000008141 laxative Substances 0.000 claims 1
- 230000002475 laxative effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 239000002357 osmotic agent Substances 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000003330 peritoneal dialysis fluid Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Claims (21)
1. Sastav, koji sadrži:
a) spoj koji je odabran iz skupine koju čine maltoza, glicerol, aminokiselina, oligopeptid, ili smjesa jednog ili više njih, u sadržaju od 5 do 75 mas.% od ukupne mase a)-d),
b) glukozu u sadržaju manjem od 1/2 sadržaja a) i u ukupnom sadržaju manjem od 5 mas.% od ukupne mase a)-d),
c) molekule glukana DP 3 i DP 4, uzete zajedno, u sadržaju manjem od 1/2 sadržaja a),
d) molekule glukana DP>4 u sadržaju da daju 100 mas.% zajedno sa a), b) i c), pri čemu
- molekule glukana DP>10 prisutne su u količini od 15-80 mas.% od ukupne mase a)-d),
- molekule glukana DP>24 prisutne su u količini od 2-60 mas.% od ukupne mase a)-d),
- molekule glukana DP>55 prisutne su u količini manjoj od 15 mas.% od ukupne mase a) -d).
2. Sastav prema zahtjevu 1, naznačen time da
- maseni prosjek molekulske mase a)-d), uzete zajedno, je Mw 0,8 - 15 kD i
- brojčani prosjek molekulske mase a)-d), uzete zajedno, iznosi Mn 0,2 – 3kD.
3. Sastav prema zahtjevu 1 ili 2, naznačen time da su molekule glukana DP>111 prisutne u količini manjoj od 1,5 mas.%.
4. Sastav prema jednom ili više prethodnih zahtjeva, naznačen time da su molekule glukana DP>246 prisutne u količini manjoj od 0,6 mas.%.
5. Sastav prema jednom ili više prethodnih zahtjeva, naznačen time da su molekule glukana DP>10 prisutne u količini od 20-80 mas.%.
6. Sastav prema jednom ili više prethodnih zahtjeva, naznačen time da su molekule glukana DP>10 prisutne u količini od 35-80 mas.%.
7. Sastav prema jednom ili više prethodnih zahtjeva, naznačen time da sadrži glukozu u sadržaju manjem od 1/3 sadržaja a).
8. Sastav prema jednom ili više prethodnih zahtjeva, naznačen time da sadrži glukozu u sadržaju od najmanje 0,1 mas.%.
9. Sastav prema jednom ili više prethodnih zahtjeva, naznačen time da sadrži molekule glukana DP 3 i DP 4, uzete zajedno, u sadržaju manjem od 1/3 sadržaja a).
10. Sastav prema jednom ili više prethodnih zahtjeva, naznačen time da sadrži molekule glukana DP 3 i DP 4, uzete zajedno, u sadržaju od najmanje 0,1 mas.%.
11. Sastav prema jednom ili više prethodnih zahtjeva, naznačen time da sadrži spoj a) ili smjesu spojeva a) u sadržaju od 8 do 65 mas.%.
12. Sastav prema jednom ili više prethodnih zahtjeva, naznačen time da sadrži molekule glukana DP>4 u sadržaju više od 16 mas.% od ukupne mase a) -d).
13. Sastav prema jednom ili više prethodnih zahtjeva, naznačen time da su molekule glukana derivatizirane.
14. Sastav prema jednom ili više prethodnih zahtjeva, naznačen time da je komponenta a) maltoza, glicerol, oligopeptid, ili smjesa jednog ili više njih.
15. Sastav prema jednom ili više prethodnih zahtjeva, naznačen time da sadrži molekule glukana DP 3 i DP 4, uzete zajedno, u sadržaju manjem od 15 mas.% ukupne mase a)-d).
16. Tekući vodenasti sastav, naznačen time da sadrži pripravak prema jednom ili više zahtjeva 1-15 i vodu.
17. Tekući vodenasti sastav prema zahtjevu 16, naznačen time da ima osmolalnost od 280 do 450 mosm/kg.
18. Sastav prema jednom ili više zahtjeva 1-15 ili tekući vodenasti sastav prema jednom ili više zahtjeva 16-17 za upotrebu kao lijek ili za upotrebu u terapiji.
19. Sastav prema jednom ili više zahtjeva 1-15, ili tekući vodenasti sastav prema jednom ili više zahtjeva 16-17 za upotrebu kao
- peritonealna terapijska tekućina ili otopina,
- dijalizna tekućina ili otopina, posebno peritonealna dijalizna tekućina ili otopina
- gastroenterološka otopina, kao što su otopine za čišćenje probavnog trakta,
- hranjiva otopina
- prehrambena infuzija,
- otopina za primjenu lijeka
- otopina za detoksikaciju
- fiziološka zamjena ili dodatak, posebno za fiziološke tjelesne tekućine, još posebnije kao zamjena ili dodatak za krv, plazmu, serum ili intersticijske tjelesne tekućine
- otopina za smanjenje adhezije nakon operacije,
- otopina za klistir,
- laksativ,
- osmotski agens, posebno osmotski pokretač
- prehrana za dojenčad
- sredstvo sa smanjenom citotoksičnošću
ili u liječenju bubrežnih bolesti.
20. Postupak za proizvodnju tekućeg vodenastog sastava prema zahtjevu 16 ili 17 ili sastava jednog ili više zahtjeva 1-15, koji obuhvaća
- pripremu vodenaste otopine škroba, sa sadržajem krutina od 10 mas.% do 60 mas.%;
- želatinizaciju, tretiranjem navedene otopine uzastopno s određenom kombinacijom enzima odabranih iz amiloglukozidaza i / ili amilaza,
- pročišćavanje otopine,
- frakcioniranje otopine na način da se eliminiraju ili smanje molekulske mase frakcije saharida koje imaju molekulsku masu veću od 40000 D i oporabu ostalih frakcija,
- dodavanje spoja koji je odabran iz skupine koja se sastoji od maltoze, glicerola, aminokiseline, oligopeptida ili smjese jednog ili više njih, i po želji glukoze
pri čemu se dobiva sastav prema jednom ili više zahtjeva 1-15 ili tekući pripravak prema jednom ili više zahtjeva 16-17.
21. Spremnik ili komplet koji sadrži barem jedan odjeljak, koji sadrži tekući vodenasti sastav jednog ili više zahtjeva 16-17 ili sastav jednog ili više zahtjeva 1-15.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17164425.5A EP3381484A1 (en) | 2017-03-31 | 2017-03-31 | Carbohydrate composition for dialysis |
EP18714471.2A EP3600486B1 (en) | 2017-03-31 | 2018-03-22 | Carbohydrate composition for dialysis |
PCT/EP2018/057275 WO2018146345A1 (en) | 2017-03-31 | 2018-03-22 | Carbohydrate composition for dialysis |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210718T1 true HRP20210718T1 (hr) | 2021-06-11 |
Family
ID=58489186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210718TT HRP20210718T1 (hr) | 2017-03-31 | 2021-05-07 | Ugljikohidratni sastav za dijalizu |
Country Status (24)
Country | Link |
---|---|
US (1) | US20200397814A1 (hr) |
EP (2) | EP3381484A1 (hr) |
JP (3) | JP2020515323A (hr) |
KR (1) | KR102180431B1 (hr) |
CN (1) | CN110520171B (hr) |
AR (1) | AR111313A1 (hr) |
AU (1) | AU2018218354C1 (hr) |
BR (1) | BR112019020586A2 (hr) |
CA (1) | CA3055677C (hr) |
CO (1) | CO2019010663A2 (hr) |
CY (1) | CY1124029T1 (hr) |
DK (1) | DK3600486T3 (hr) |
ES (1) | ES2864403T3 (hr) |
HR (1) | HRP20210718T1 (hr) |
HU (1) | HUE053951T2 (hr) |
LT (1) | LT3600486T (hr) |
MX (1) | MX2019011646A (hr) |
PL (1) | PL3600486T3 (hr) |
PT (1) | PT3600486T (hr) |
RS (1) | RS61757B1 (hr) |
RU (1) | RU2749443C2 (hr) |
SI (1) | SI3600486T1 (hr) |
TW (1) | TWI763817B (hr) |
WO (1) | WO2018146345A1 (hr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3381484A1 (en) | 2017-03-31 | 2018-10-03 | Opterion Health AG | Carbohydrate composition for dialysis |
CN110483649A (zh) * | 2019-08-28 | 2019-11-22 | 西安乐析医疗科技有限公司 | 一种新型糊精的制备方法及其在透析液中的应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4182756A (en) | 1977-11-21 | 1980-01-08 | Abbott Laboratories | High calorie solutions of low molecular weight glucose polymer mixtures useful for intravenous administration |
FR2445839A1 (fr) | 1979-01-08 | 1980-08-01 | Roquette Freres | Hydrolysat d'amidon eventuellement hydrogene, son procede de preparation et ses applications |
WO1983000087A1 (en) | 1981-07-10 | 1983-01-20 | Baxter Travenol Lab | Peritoneal dialysis solution containing carbohydrate polymers |
EP0076355A3 (en) | 1981-10-01 | 1983-05-25 | Abbott Laboratories | Improved peritoneal dialysis solution |
GB8300718D0 (en) | 1983-01-12 | 1983-02-16 | Milner Research Ireland Ltd | Glucose polymer solutions |
GB8404299D0 (en) * | 1984-02-18 | 1984-03-21 | Milner Research Ireland Ltd | Peritoneal dialysis |
US4886789A (en) | 1983-01-12 | 1989-12-12 | M. L. Laboratories Plc | Peritoneal dialysis and compositions for use therein |
US6077836A (en) * | 1983-01-12 | 2000-06-20 | Ml Laboratotries, Plc | Peritoneal dialysis and compositions for use therein |
ATE106410T1 (de) * | 1985-06-22 | 1994-06-15 | Ml Lab Plc | In kontinuierlicher peritonealdialyse verwendete polymere. |
US6248726B1 (en) | 1985-06-22 | 2001-06-19 | M L Laboratories Plc | Method of peritoneal dialysis using glucose polymer solutions |
DE4123001A1 (de) * | 1991-07-11 | 1993-01-14 | Laevosan Gmbh & Co Kg | Pharmazeutische zusammensetzung fuer die peritonealdialyse |
US6306836B1 (en) | 1994-01-21 | 2001-10-23 | Baxter International Inc. | Peritoneal dialysis solutions containing maltodextrins and amino acids |
FR2840612B1 (fr) * | 2002-06-06 | 2005-05-06 | Roquette Freres | Polymeres solubles de glucose hautement branches et leur procede d'obtention |
FR2864088B1 (fr) * | 2003-12-19 | 2006-04-28 | Roquette Freres | Polymeres solubles de glucose hautement branches |
JP5415939B2 (ja) | 2006-04-28 | 2014-02-12 | バイエル・クロップサイエンス・アーゲー | 超長鎖のイヌリン |
FR2955861B1 (fr) * | 2010-02-02 | 2013-03-22 | Roquette Freres | Polymeres solubles de glucose branches pour la dialyse peritoneale |
US8724336B2 (en) | 2010-07-02 | 2014-05-13 | National Instruments Corporation | Card guide system and method |
MX362554B (es) * | 2011-03-18 | 2019-01-24 | Baxter Healthcare Sa | Soluciones de dialisis peritoneal que comprenden polimeros de glucosa. |
AU2013252433B2 (en) * | 2012-04-24 | 2017-12-14 | The University Of British Columbia | Polymer-based dialysate |
EP3120842A1 (en) * | 2015-07-20 | 2017-01-25 | Opterion Health AG | Peritoneal therapeutic fluid |
EP3381484A1 (en) | 2017-03-31 | 2018-10-03 | Opterion Health AG | Carbohydrate composition for dialysis |
-
2017
- 2017-03-31 EP EP17164425.5A patent/EP3381484A1/en not_active Withdrawn
-
2018
- 2018-03-22 CN CN201880023467.4A patent/CN110520171B/zh active Active
- 2018-03-22 PL PL18714471T patent/PL3600486T3/pl unknown
- 2018-03-22 SI SI201830232T patent/SI3600486T1/sl unknown
- 2018-03-22 PT PT187144712T patent/PT3600486T/pt unknown
- 2018-03-22 ES ES18714471T patent/ES2864403T3/es active Active
- 2018-03-22 MX MX2019011646A patent/MX2019011646A/es unknown
- 2018-03-22 RU RU2019134107A patent/RU2749443C2/ru active
- 2018-03-22 KR KR1020197028685A patent/KR102180431B1/ko active IP Right Grant
- 2018-03-22 WO PCT/EP2018/057275 patent/WO2018146345A1/en unknown
- 2018-03-22 CA CA3055677A patent/CA3055677C/en active Active
- 2018-03-22 BR BR112019020586A patent/BR112019020586A2/pt unknown
- 2018-03-22 US US15/780,214 patent/US20200397814A1/en active Pending
- 2018-03-22 EP EP18714471.2A patent/EP3600486B1/en active Active
- 2018-03-22 LT LTEP18714471.2T patent/LT3600486T/lt unknown
- 2018-03-22 RS RS20210496A patent/RS61757B1/sr unknown
- 2018-03-22 AU AU2018218354A patent/AU2018218354C1/en active Active
- 2018-03-22 DK DK18714471.2T patent/DK3600486T3/da active
- 2018-03-22 HU HUE18714471A patent/HUE053951T2/hu unknown
- 2018-03-22 JP JP2019552910A patent/JP2020515323A/ja active Pending
- 2018-03-28 AR ARP180100773A patent/AR111313A1/es unknown
- 2018-03-30 TW TW107111274A patent/TWI763817B/zh active
-
2019
- 2019-09-27 CO CONC2019/0010663A patent/CO2019010663A2/es unknown
-
2021
- 2021-04-05 JP JP2021064226A patent/JP7126091B2/ja active Active
- 2021-04-14 CY CY20211100327T patent/CY1124029T1/el unknown
- 2021-05-07 HR HRP20210718TT patent/HRP20210718T1/hr unknown
-
2022
- 2022-07-22 JP JP2022117201A patent/JP7411268B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210718T1 (hr) | Ugljikohidratni sastav za dijalizu | |
Paul et al. | Chitosan and its derivatives-biomaterials with diverse biological activity for manifold applications | |
JP2010535188A (ja) | 関節疾患若しくは関節痛の治療用又は審美的な目的若しくは他の目的のための皮膚の治療用の方法及び化合物並びに化合物の調製方法 | |
CN103800278B (zh) | 透明质酸联合聚桂醇在制备治疗静脉畸形泡沫硬化药物中的应用 | |
WO2003090763A1 (en) | Composition and kit for the treatment of inflammatory bowel diseases | |
WO2015142924A1 (en) | Multivalent cation formulations of partially desulfated heparins | |
US20230000904A1 (en) | Anti-hemorrhaging compositions | |
CN106822986B (zh) | 一种壳聚糖-琼胶低聚糖多孔球珠止血材料的制备方法 | |
EP2560661B1 (en) | Use of the modified polysaccharides for heparin neutralization | |
CN108888592A (zh) | 一种低分子量肝素钠注射液及其制备方法 | |
CN104622894A (zh) | 一种血液净化置换液 | |
CN107375318A (zh) | 壳寡糖腹膜透析液 | |
CN102755663A (zh) | 一种医用生物胶体液的配方及制备方法 | |
CN108261560A (zh) | 一种含变性淀粉纳米粒的可降解吸收止血材料及其应用 | |
CN101181643A (zh) | 生物液泡敷料及其制备方法 | |
CN108524539B (zh) | 一种平衡盐冲洗液的药物组合物 | |
JPH06279292A (ja) | 生理活性を有するグリコーゲンの製法及び生理活性 | |
Lin et al. | Application of citric acid in continuous veno-venous hemofiltration of severe acute pancreatitis patients in ICU | |
CN104887697A (zh) | 氨基多糖季铵盐组合物及其应用、制剂 | |
CN101301308A (zh) | Dft在制备治疗和预防弥散性血管内凝血药物中的应用 | |
CN103040899B (zh) | 痔瘘中药无创性药物及其制备方法和使用方法 | |
CN101450064A (zh) | 一种人参皂苷或其混合物的药物用途 | |
KR20150120277A (ko) | C형 바이러스 간염 치료제 | |
UA68867A (en) | GLYCOSTERYL F5 û CARBOHYDRATE CONTAINING ELECTROLYTIC SOLUTION FOR INFUSIONS |